<DOC>
	<DOCNO>NCT01215214</DOCNO>
	<brief_summary>Identification evaluation endogenous marker assessment CYP3A activity use metabolomics .</brief_summary>
	<brief_title>Identification Evaluation Endogenous Markers Assessment CYP3A Activity Using Metabolomics</brief_title>
	<detailed_description>Eligibility participation study determine demographic information , medical history , physical examination , electrocardiogram ( ECG ) clinical laboratory test within 3 week study drug administration . Subjects suitable study admit Clinical Trials Center , Seoul National University Hospital day dose , overnight-fasted 10 p.m. Day -1 . Urine collection schedule drug 24 hour midazolam administration . Subjects dose study drug via intravenous around 9 a.m. Day 1 . Subjects perform scheduled procedure include clinical laboratory test , electrocardiogram pharmacokinetic sampling . Subjects discharge Day 2 , visit Clinical Trials Center Day 5-7 ketoconazole administration . Subjects admit Day 7 period 2 . Subjects perform scheduled period 2 ( ketoconazole co-administration phase ) , period 3 ( rifampicin co-administration phase ) procedure . Study participation terminate post-study visit ( Day 30-32 ) .</detailed_description>
	<mesh_term>Midazolam</mesh_term>
	<criteria>Age : Between 20 50 year age , inclusive Weight : Between 50 95 kg , within 1728 Body Mass Index Subject reliable willing make available study period , willing follow study protocol , give write informed consent voluntarily History hypersensitive reaction medication ( midazolam , ketoconazole , rifampicin ) History significant clinical illness need medical caution , include cardiovascular , immunologic , hematologic , neuropsychiatric , respiratory , gastrointestinal , hepatic , renal disease chronic disease History evidence drug abuse Use prescriptive medication , Korean traditional medication consider acceptable clinical investigator last 14 day period first dose , use OTC medication consider acceptable clinical investigator last 7 day period first dose ( use medication consider acceptable investigator , patient include ) Participation clinical trial drug within 60 day prior participation study Judged inappropriate study investigator</criteria>
	<gender>Male</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2011</verification_date>
	<keyword>metabolite profile</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>CYP3A</keyword>
	<keyword>metabolomics</keyword>
</DOC>